2026
article
OpenAlex
María González‐Esguevillas, Aaron F. Baldwin, Pablo J. Cabrera, Yanfei Guan et autres
Abstract Ibuzatrelvir is an orally bioavailable, next-generation clinical candidate developed for the treatment of COVID-19 infections. It was identified during the pandemic, prior to the approval of PAXLOVID, and displays a more favorable pharmacokinetic profile than nirmatrelvir. Consequently, the initial development of …
us
(code pays fourni par la source)
2026
article
OpenAlex
Russell F. Algera, Christophe Allais, Aaron F. Baldwin, Gabrielle E. Cabrera et autres
Abstract Ibuzatrelvir is a second-generation, orally administered protease inhibitor of the SARS-CoV-2 MPro virus that is currently being evaluated for the treatment of Covid-19. The molecule contains a substituted trans-trifluoromethylproline fragment that, although it had been the focus of previous synthetic efforts, …
us
(code pays fourni par la source)
2024
article
OpenAlex
Russell F. Algera, Christophe Allais, Pablo J. Cabrera, María González‐Esguevillas et autres
Ibuzatrelvir ( 1 ) is a second-generation, orally bioavailable, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor clinical candidate. Herein, we report the implementation of an in silico and high-throughput experimentation strategy leading to the identification of a rapid, efficient, …
us
(code pays fourni par la source)